Ambrisentan not effective in idiopathic pulmonary fibrosis

Ambrisentan not effective in idiopathic pulmonary fibrosis
The endothelin A receptor-selective antagonist ambrisentan is not effective for reducing the rate of idiopathic pulmonary fibrosis progression, according to a study published in the May 7 issue of the Annals of Internal Medicine.

(HealthDay)—The endothelin A receptor-selective antagonist ambrisentan is not effective for reducing the rate of idiopathic pulmonary fibrosis (IPF) progression, according to a study published in the May 7 issue of the Annals of Internal Medicine.

To examine whether ambrisentan reduces the rate of IPF progression, Ganesh Raghu, M.D., from the University of Washington in Seattle, and colleagues randomized patients (aged 40 to 80 years) with IPF, with minimal or no honeycombing on high-resolution computed tomography scans, to receive ambrisentan (10 mg/day) or placebo.

Noting that interim analysis indicated a low likelihood of showing efficacy for the end point by the scheduled end of the study, the researchers terminated the study after enrollment of 492 patients (75 percent of intended enrollment; mean duration of exposure to study medication, 34.7 weeks). There was a significantly increased likelihood of meeting the prespecified criteria for disease progression among the ambrisentan-treated versus placebo-treated patients (27.4 percent versus 17.2 percent; hazard ratio, 1.74). The decline in lung function was seen in 16.7 percent of ambrisentan-treated patients and in 11.7 percent of placebo-treated patients (P = 0.11). Respiratory hospitalizations were significantly higher in the ambrisentan group than the (13.4 versus 5.5 percent, respectively). There was a nonsignificant difference in the number of deaths between the two groups (7.9 percent of ambrisentan-treated and 3.7 percent of placebo-treated patients; P = 0.10).

"Ambrisentan was not effective in treating IPF and may be associated with an increased risk for disease progression and respiratory hospitalizations," the authors write.

Several authors disclosed to pharmaceutical companies, including Gilead Sciences, which funded the study.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Vitreolytic ocriplasmin resolves vitreomacular traction

Aug 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse ...

Recommended for you

Swatting chikungunya

4 hours ago

Summer days may be waning, but health officials are still on high alert for new cases of chikungunya, a painful mosquito-borne virus that spread to the United States from the tropics earlier this year. ...

Sierra Leone readies for controversial Ebola lockdown

4 hours ago

Sierra Leone prepared Thursday for an unprecedented three-day nationwide lockdown to contain the deadly spread of the Ebola virus in a controversial move which experts claimed could worsen the epidemic.

Nepal adopts jab to boost polio fight

4 hours ago

Nepal on Thursday launched a drive to eradicate polio by supplementing oral vaccines with an injection that experts say will boost children's immunity against the disease.

User comments